| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000022989 |
| Receipt No. | R000007606 |
| Official scientific title of the study | Comparative study of once vs. twice daily regimen of double dose of rabeprazole in uncontrolled GERD patients taking usual dose of proton pump inhibitors. |
| Date of disclosure of the study information | 2016/07/02 |
| Last modified on | 2017/01/04 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | Comparative study of once vs. twice daily regimen of double dose of
rabeprazole in uncontrolled GERD patients taking usual dose of proton pump inhibitors. |
|
| Title of the study (Brief title) | Once vs. twice daily regimen of double dose PPI in GERD | |
| Region |
|
|
| Condition | ||
| Condition | Gastro-Esophageal Reflux Disease | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Clarify the effectiveness of once or twice daily regimen of double dose of rabeprazole in uncontrolled GERD patients taking usual dose of proton pump
inhibitors. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Improvement of GERD symptoms,sleep disturbance and QOL |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -no one is blinded |
| Control | Active |
| Stratification | NO |
| Dynamic allocation | NO |
| Institution consideration | Institution is not considered as adjustment factor. |
| Blocking | NO |
| Concealment | Numbered container method |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Twice per day divided administration method | |
| Interventions/Control_2 | Once per day administration method | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Subjects who have received upper GI endoscopic examination during 4 weeks before the clinical trial starts
.Subjects who have not received two-fold dose administration of PPI during 4 weeks before the clinical trial starts Subjects who give informed consent by written from themselves or family members |
|||
| Key exclusion criteria | Subjects who have any mental disorders
Subjects who have histories of allergy against laperazol Subjects who have serious complications and problems to continue to perform this clinical trial Subjects who are pregnant, possibly pregnant, or feeding her children Subjects who cannot accept an upper GI endoscopic examination Subjects who have two-fold dose of PPI during 4 weeks before the clinical trial starts Subjects who are decided to be unacceptable for this clinical trial by their clinical physicians |
|||
| Target sample size | 100 | |||
| Research contact person | |
| Name of lead principal investigator | Akira Mizuki |
| Organization | Keiyu Hospital |
| Division name | Internal medicine |
| Address | 3-7-3 Minatomirai,Nishi-ku,Yokohama |
| TEL | 045-221-8181 |
| a-mizuki@keiyu-hospital.com | |
| Public contact | |
| Name of contact person | Akira Mizuki |
| Organization | Keiyu Hospital |
| Division name | Internal medicine |
| Address | 3-7-3 Minatomirai,Nishi-ku,Yokohama |
| TEL | 045-221-8181 |
| Homepage URL | |
| a-mizuki@keiyu-hospital.com | |
| Sponsor | |
| Institute | Keiyu Hospital
Internal Medicine |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Keiyu Hospital
Internal Medicine |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Published |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007606 |